Centessa Pharmaceuticals (CNTA) Tax Provisions (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Tax Provisions of $850000.0 for Q1 2026, down 39.16% year-over-year from $1.4 million in Q1 2025, and up 262.84% on a QoQ basis from -$522000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Tax Provisions data on file, last reported at $850000.0 in Q1 2026.
- Quarterly Tax Provisions fell 39.16% year-over-year to $850000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 66.17% YoY) and the FY2025 annual result came in at $1.8 million, down 36.04% from the prior year.
- Tax Provisions grew to $850000.0 in Q1 2026 per CNTA's latest filing, from -$522000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $1.4 million in Q1 2025 and bottomed at -$24.1 million in Q2 2023.
- The 5-year median for Tax Provisions is $481000.0 (2024), against an average of -$1.2 million.
- Peak annual rise in Tax Provisions reached 746.25% in 2023, while the deepest fall reached 109222.73% in 2023.
- Tracing CNTA's Tax Provisions over 5 years: stood at -$664000.0 in 2022, then jumped by 272.29% to $1.1 million in 2023, then fell by 8.22% to $1.0 million in 2024, then slumped by 149.71% to -$522000.0 in 2025, then soared by 262.84% to $850000.0 in 2026.
- Per Business Quant, the three latest CNTA Tax Provisions figures stand at $850000.0 (Q1 2026), -$522000.0 (Q4 2025), and $166000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 850,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 850,000.00 |
| Dec 31, 2025 | -522,000.00 |
| Sep 30, 2025 | 166,000.00 |
| Jun 30, 2025 | 778,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 608,000.00 |
| Jun 30, 2024 | 705,000.00 |
| Mar 31, 2024 | 481,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | -2.83 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | 677,000.00 |
| Dec 31, 2022 | -664,000.00 |
| Sep 30, 2022 | -100,000.00 |
| Jun 30, 2022 | -22,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Dec 31, 2021 | 114,000.00 |